How Ethics Committees Ensure Ongoing Oversight During Clinical Trials

Introduction: Ethical Review Doesn’t End with Approval

Ethical approval of a clinical trial is not a one-time event. Once a study begins, ethics committees (also known as Institutional Review Boards or IRBs) are obligated to provide continuous oversight to safeguard participants’ rights, safety, and well-being throughout the entire trial lifecycle. Regulatory bodies like ICH-GCP, FDA, EMA, and CDSCO mandate that ethical review continues in real-time as new information becomes available, such as safety concerns, protocol amendments, or deviations.

This ongoing process ensures that risks remain acceptable, consent procedures stay relevant, and researchers remain accountable. This article outlines the essential components and best practices of continuous ethics oversight in clinical research.

1. The Regulatory Basis for Continuing Ethics Review

Globally recognized standards mandate continuous ethical monitoring. For example:

• ICH E6 (R2) GCP: Section 3.1 outlines that an EC must conduct continuing review at intervals appropriate to the degree of risk.
• FDA 21 CFR 56.109(f): Requires review at least annually, and more often for high-risk studies.
• EU Clinical Trials Regulation (EU CTR 536/2014): Incorporates ongoing safety updates and amendment approvals.
• Indian NDCT Rules, 2019: Mandates continued EC review and SAE oversight during the study.

These frameworks form the backbone of dynamic oversight, shifting ethics from a one-time checkpoint to an ongoing compliance commitment.

2. Scheduled Continuing Reviews: Annual and Interim

Most Ethics Committees conduct formal continuing reviews either annually or based on study risk profile. At these intervals, investigators submit an “Annual Progress Report” (APR) or “Continuing Review Application” (CRA) covering:

• Recruitment status and demographic summary
• List of adverse events (AEs), serious AEs (SAEs), and SUSARs
• Summary of protocol deviations and corrective actions
• Amendments and re-consents issued
• Ongoing risk-benefit assessment

Ethics Committees may request additional documentation such as DSMB reports or audit findings during review.

3. Protocol Amendments: Ethics Review Before Implementation

Changes to the protocol—whether administrative, scientific, or safety-related—must be submitted to the EC before implementation. Examples include:

• Eligibility criteria changes
• Dose modification or route of administration
• Extension of study duration
• Changes in recruitment or ICF materials

Most regulatory frameworks prohibit initiating these changes without EC review and approval, unless immediate implementation is necessary to eliminate apparent hazards.

4. Ongoing Review of Informed Consent and Re-Consent

Informed consent is not static. Continuous ethics oversight includes monitoring changes that require re-consenting participants. These may arise from:

• New risk information (e.g., post-marketing AE reports)
• Protocol changes that affect participant expectations
• Revised compensation structures or visit schedules

The EC ensures revised ICFs are appropriately translated, approved, and implemented with documentation of participant re-consent.

5. SAE Reporting and Ethics Committee Monitoring

SAEs and SUSARs must be reported to the EC in accordance with regulatory timelines. For example:

The EC evaluates these reports to determine if the study’s risk profile has changed and whether participant safety remains acceptable.

6. Ethics Oversight of Protocol Deviations and Noncompliance

Protocol deviations are inevitable in long studies, but must be logged, reported, and reviewed by the EC. Examples include:

• Missed visits or lab assessments
• Improper consent procedures
• Enrollment of ineligible subjects

Recurring deviations may trigger EC-mandated corrective actions, site re-training, or even study suspension.

7. Site Monitoring Reports and Ethics Audits

ECs may request periodic monitoring reports from the sponsor/CRO or perform their own site visits to ensure compliance. Key checkpoints include:

• Proper ICF storage and versioning
• Trial master file (TMF) updates
• Adverse event follow-up documentation
• Protocol adherence logs

Independent EC audits are more common in high-risk trials or those involving vulnerable populations.

8. Oversight of Data Monitoring Committees (DMC/DSMB)

For blinded or large-scale trials, ECs often review Data Monitoring Committee (DMC or DSMB) charters and reports to assess interim safety. They may evaluate:

• Unblinded safety signals
• Early stopping criteria
• Protocol continuation recommendations

The EC may even require submission of DMC minutes for high-risk studies (e.g., oncology, gene therapy).

9. External Factors Triggering EC Re-review

Even beyond sponsor-initiated updates, the EC must remain vigilant to external developments that may impact the ethical viability of a trial. Examples include:

• New safety data from global studies
• Drug withdrawal by another regulatory agency
• Updated treatment guidelines
• Negative media coverage affecting public perception

Ethics Committees must evaluate whether continued trial conduct remains justified in such scenarios.

10. Documentation and Archival of Oversight Activities

Regulations require that all ethical oversight activities be properly documented and archived. This includes:

• Minutes of continuing review meetings
• Approval letters for amendments and annual reviews
• SAE communications and decisions
• Re-consent tracking logs

This documentation is subject to audit by regulatory agencies and must be retained for a minimum duration (e.g., 5 years post-trial in EU, 3 years in US).

Conclusion: Making Ethics Oversight an Active Process

Continuous ethics oversight ensures that the dynamic nature of clinical trials is matched by an equally responsive ethical review process. From monitoring SAEs and amendments to tracking re-consents and deviations, ethics committees play a crucial role in upholding the rights and safety of participants throughout the trial lifecycle.

By adopting proactive review schedules, digital reporting systems, and training for real-time risk assessment, ECs can move from passive reviewers to engaged guardians of participant welfare.

How to Obtain Ethical Approvals for Case-Control Data Collection in Pharma Studies

Case-control studies play a pivotal role in real-world evidence (RWE) generation, especially in assessing rare diseases, adverse drug reactions, and pharmacoepidemiological outcomes. However, like any human subject research, these studies must adhere to strict ethical standards. Pharmaceutical professionals conducting retrospective or prospective data collection need a clear roadmap for obtaining institutional ethics approvals, particularly for observational studies with minimal risk.

This tutorial explains how to prepare and submit ethical approval applications for case-control data collection in accordance with pharmaceutical compliance expectations, global regulations, and Good Clinical Practice (GCP).

Understanding the Role of Ethics Committees in Observational Research:

In most countries, any study involving human subjects, even if observational and retrospective, must undergo ethical review. Institutional Review Boards (IRBs) or Independent Ethics Committees (IECs) assess whether the data collection process respects participant rights, privacy, and safety.

• For prospective case-control studies, informed consent is usually mandatory.
• For retrospective chart reviews or de-identified data, a waiver of consent may be sought.
• Multi-site studies may require centralized or site-specific ethical approvals.

According to USFDA guidance, even retrospective reviews may need IRB approval unless specific exemption criteria are met.

Key Documents Required for IRB Submission:

Pharma professionals should prepare a robust IRB application package containing:

1. Study Protocol: Clearly describing objectives, methods, data sources, statistical plan, and ethical considerations.
2. Informed Consent Form (if applicable): For prospective data collection.
3. Data Collection Instruments: CRFs, eCRFs, or survey tools to be used.
4. Data Privacy Plan: Explaining how data will be de-identified and stored securely.
5. Justification for Waiver of Consent: For retrospective studies involving no direct subject contact.
6. Investigator CV and Site Compliance Information: As part of GMP documentation.

Informed Consent Requirements for Case-Control Studies:

Consent obligations vary based on the type of study:

• Retrospective Studies: If data is de-identified or pre-existing (e.g., from EHRs), IRBs may waive consent.
• Prospective Studies: Consent is almost always required, especially if biological samples or interviews are involved.
• Nested Case-Control Studies: Consent may already be covered under the parent cohort’s consent, but this should be confirmed with the IRB.

Proper documentation of informed consent or its waiver must be maintained per pharma SOP templates.

Common Ethical Issues in Case-Control Data Collection:

Even if minimal risk is involved, ethical pitfalls can arise. Common challenges include:

• Insufficient justification for accessing patient records without consent
• Over-collection of identifiable information beyond study needs
• Lack of clarity on who will have data access
• Re-identification risks when combining datasets

Best Practices:

1. Define the data minimization principle—collect only what’s needed.
2. Use coded identifiers or pseudonymized data wherever possible.
3. Submit a Data Management Plan (DMP) to the IRB.
4. Ensure that data is stored in encrypted, access-controlled environments.

Global Regulations and Observational Study Ethics:

Observational research ethics are guided by international and national frameworks:

• ICH GCP E6 (R2): Emphasizes ethical review and data protection for all clinical investigations.
• EU GDPR: Requires lawful basis and transparency for processing personal data.
• HIPAA (USA): Governs use of Protected Health Information (PHI) and permits IRB waivers under certain conditions.
• Indian Council of Medical Research (ICMR): Provides observational research guidance for India, emphasizing EC approval even for retrospective studies.

Always include a compliance section in your protocol referring to applicable local or international standards.

Ethical Considerations for Secondary Data Use:

Using data from biobanks, registries, or insurance claims requires ethical scrutiny. Even if the data is anonymized, you must:

• Ensure proper data use agreements are in place
• Assess re-identification risks with combined datasets
• Submit details of source, access rights, and data management to the IRB

These considerations align with best practices in stability studies in pharmaceuticals and other non-interventional research.

Submitting a Request for Waiver of Consent:

For retrospective data collection, you may apply for a waiver of consent by demonstrating:

1. Minimal risk to participants
2. No adverse effect on rights and welfare
3. Impracticability of conducting the research without the waiver
4. Adequate plan to protect confidentiality

Include a waiver justification document, which may be reviewed more stringently by ethics committees handling RWE studies.

Ethics Review Timeline and Approval Process:

The typical process for ethical review involves:

• Initial review of submission completeness (1–2 weeks)
• Full board or expedited review based on risk level (2–4 weeks)
• Request for clarifications or modifications (if needed)
• Final approval letter with conditions (if any)

Plan your study timelines to accommodate this ethical review cycle and any necessary modifications.

Maintaining Compliance During and After the Study:

Post-approval, ensure continued compliance by:

• Reporting protocol deviations to the IRB
• Submitting progress reports or continuing review applications
• Notifying the IRB of study closure and data archiving plans
• Auditing consent documentation or electronic logs

These activities should be documented in alignment with validation master plans and sponsor SOPs.

Checklist for Pharma Professionals Seeking Ethical Approval for Case-Control Studies:

• Complete protocol with ethical considerations section
• Clear data protection plan
• Consent form or waiver justification
• Data source and access rights confirmation
• IRB/IEC submission letter and institutional approvals
• Investigator training and GCP compliance record

Conclusion: Prioritizing Ethics in Observational Study Planning

Ethical integrity is as critical in case-control studies as in interventional clinical trials. Ethical review ensures that participant rights are protected and that your study aligns with global expectations for real-world evidence generation. Whether your data comes from hospitals, EHRs, biobanks, or registries, securing ethical approval is a foundational step toward study success and scientific credibility.

By following the outlined steps, aligning with GMP compliance, and maintaining transparent communication with IRBs, you’ll enhance your study’s acceptance and minimize ethical risks in the long run.